Article Text

Download PDFPDF
Corticosteroids in herpes simplex virus encephalitis
  1. H Openshaw,
  2. E M Cantin
  1. Departments of Neurology and Virology, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA
  1. Correspondence to:
 Dr Harry Openshaw
 City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010, USA;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The effectiveness of corticosteroids in herpes simplex virus encephalitis is not proven

Despite receiving standard antiviral therapy, an appreciable number of patients with herpes simplex virus encephalitis (HSVE) experience poor acute outcome or delayed neurological progression. It is uncertain whether all poor outcomes are due to viral cytopathology or whether an immune mediated pathogenesis also occurs. In support of an immunopathological cause, Kamei et al (see pages XX–XX of this issue) report that corticosteroid administration was a significant predictor of favourable outcome at 3 months after HSVE infection.

Immune cells persist and elaborate cytokines in the nervous system long after the virus has entered latency.1 It is …

View Full Text